Vascular-disrupting agents are a promising new class of oncology drugs that show synergistic effects when combined with conventional cytotoxic agents.
No takes yet. Share an insight, caveat, or question.
May support trial evaluation of combinations; leaves open clinical adoption pending randomized data.
Mita et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: